Insmed announces positive topline results from phase 2b study of treprostinil palmitil inhalation powder (tpip) as once-daily therapy in patients with pulmonary arterial hypertension

–the study met primary and all secondary efficacy endpoints– statistically significant 35% placebo-adjusted reduction from baseline in pulmonary vascular resistance for the primary endpoint (p
INSM Ratings Summary
INSM Quant Ranking